Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PharmaCyte Biotech ( (PMCB) ) just unveiled an update.
On December 1, 2025, PharmaCyte Biotech received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, as its stock price fell below $1.00 per share for 30 consecutive business days. Although this notice does not immediately affect the company’s stock trading or operations, PharmaCyte has until June 1, 2026, to regain compliance, potentially through measures like a reverse stock split. Failure to comply could lead to delisting, but the company is actively monitoring its stock price and considering options to address the issue.
More about PharmaCyte Biotech
PharmaCyte Biotech, Inc. operates in the biotechnology industry, focusing on developing cellular therapies for cancer and diabetes. The company is known for its innovative approaches in the medical field, particularly its work on encapsulated cell technology.
Average Trading Volume: 2,830,948
Technical Sentiment Signal: Sell
Current Market Cap: $8.22M
See more data about PMCB stock on TipRanks’ Stock Analysis page.